{
  "symbol": "MXCT",
  "company_name": "Maxcyte Inc",
  "ir_website": "https://investors.maxcyte.com/",
  "structured_data": [
    {
      "section_name": "News Articles",
      "links": [
        {
          "title": "Latest News",
          "url": "https://maxcyte.com/latest-news/",
          "content": "[Skip to content](#fl-main-content)\n\n[ ![Group 167 \\(1\\)](https://maxcyte.com/wp-content/uploads/2022/11/Group-167-1.svg) ](/)\n\n[ Menu ](javascript:void\\(0\\) \"Click Here\")\n\n![Mobile logo](https://maxcyte.com/wp-content/uploads/2022/11/Mobile-logo.svg)\n\n  * Platforms\n    * [Back](#)\n    * [Electroporation Systems](/electroporation-systems/)\n  * Our Approach\n    * [Back](#)\n    * [Our Technology](/our-technology/)\n    * [Technical & Regulatory Support](/our-technology/technical-regulatory-support/)\n    * [Partnerships](/our-technology/partnerships)\n    * [Collaboration](/our-technology/collaboration)\n  * Who We Serve\n    * [Back](#)\n    * [Cell & Gene Therapy](/our-technology/cell-gene-therapy/)\n    * [Discovery](/our-technology/discovery-translational-research/)\n    * [Bioprocessing & Protein Production](/our-technology/bioprocessing-protein-production/)\n  * Learning Hub\n    * [Back](#)\n    * [Applications](/applications/)\n    * [Featured Science](/featured-science/)\n    * [Resource Library](/resource-library/)\n    * [Scientific Publications](/scientific-publications/)\n    * [Webinars & Presentations](/webinars-presentations/)\n    * [What cells can I use?](/what-cells-can-i-use/)\n  * [About Us](/about-us/)\n    * [Back](#)\n    * [Our History](/company-history/)\n    * [Our Team](/leadership/)\n    * [Board of Directors](/board-of-directors/)\n    * [Join our Team](/careers/)\n  * [Join Our Team](/careers/)\n  * News & Events\n    * [Back](#)\n    * [Press Releases](https://investors.maxcyte.com/news-events/news-releases/general)\n    * [Latest News](https://maxcyte.com/latest-news/)\n    * [Events](/events/)\n  * [Investors](https://investors.maxcyte.com/)\n  * [Contact Us](/contact/)\n    * [Back](#)\n    * [Ask the ExPERT](/contact/)\n    * [Request a Quote](/request-a-quote/)\n    * [Technical Support](/technical-support/)\n\n\n\n[](https://maxcyte.com/) Latest News\n\n#  MaxCyte Latest News\n\n[ FEATURED NEWS  On the Charge: MaxCyte Celebrates Role in Sickle Cell Therapy Breakthrough  After interviewing Maher Masoud and Jim Brady, Kevin Davies, editor of GEN, presents in this article an exploration of MaxCyte’s history, its impact on the cell and gene therapy field—especially following the casgevy approval—and a glimpse into its future. **READ ARTICLE >>** ](https://www.genengnews.com/topics/genome-editing/on-the-charge-maxcyte-celebrates-role-in-sickle-cell-therapy-breakthrough/)\n\n\n\n\nLoad More\n\n####  Receive upcoming events, new resources and more in your inbox\n\nEmail Address(Required)\n\nShowing 1-10\n\n[ ![Logo celebrating MaxCyte's 25-year anniversary](https://maxcyte.com/wp-content/uploads/2024/09/25-years-of-MaxCyte-380x340.png) ** November 13, 2024 ** MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics MaxCyte marks over a quarter-century remaining steadfast in its mission to provide the life sciences community with the necessary technologies, as well as scientific, technical and regulatory support, to develop biomedical innovations that will transform human health. ](https://investors.maxcyte.com/news-releases/news-release-details/maxcyte-celebrates-25-years-innovation-driving-cell-engineering)\n\n[ ![Logo of the Sanford Stem Cell Institute](data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20200%2095'%3E%3C/svg%3E) ** November 11, 2024 ** University of California San Diego announces collaboration with MaxCyte New collaboration aims to improve patient outcomes and boost biopharma workforce development. ](https://maxcyte.com/news/university-of-california-san-diego-announces-collaboration-with-maxcyte/)\n\n[ ![Headshot of Cynthia Collins](data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20380%20340'%3E%3C/svg%3E) ** October 15, 2024 ** MaxCyte appoints Cynthia Collins to its board of directors Cynthia Collins joins the board with extensive and impressive leadership experience in the fields of cell therapy and genetic medicine that will be invaluable to MaxCyte in the coming years. ](https://investors.maxcyte.com/news-releases/news-release-details/maxcyte-appoints-cynthia-collins-its-board-directors)\n\n[ ![](data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20380%20340'%3E%3C/svg%3E) ** October 10, 2024 ** MaxCyte appoints Ali Soleymannezhad as Chief Commercial Officer Ali Soleymannezhad will lead MaxCyte’s commercial operations to increase adoption of the ExPERT Platform, provide best-in-class scientific, technical and regulatory support to customers, and expand the company’s market impact in cell and gene therapy. ](https://investors.maxcyte.com/news-releases/news-release-details/maxcyte-appoints-ali-soleymannezhad-chief-commercial-officer)\n\n[ ![](data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20380%20340'%3E%3C/svg%3E) ** September 25, 2024 ** MaxCyte Minutes Newsletter – Q3 2024 In the last three months, Kamau Therapeutics became a strategic platform licensee partner, Porton Advance adopted the ExPERT GTx Flow Electroporation as part of their offerings, and ScaleReady and MaxCyte have collaborated on the G-Rex Grant Program to support cell and gene therapy advancements. ](https://maxcyte.com/news/maxcyte-minutes-newsletter-q3-2024/)\n\n[ ![Marina Prasek](https://maxcyte.com/wp-content/uploads/2024/09/Marina-Prasek-380x340.jpg) ** September 24, 2024 ** MaxCyte puts a focus on Marina Prasek, Director of Project Management Marina Prasek is a project and portfolio management leader with demonstrated success in new product development and commercialization that joined MaxCyte in January of 2024. ](https://maxcyte.com/news/maxcyte-minutes-newsletter-q3-2024/maxcyte-puts-a-focus-on-marina-prasek/)\n\n[ ![Kamau logo](https://maxcyte.com/wp-content/uploads/2024/09/Kamau-logo.jpg) ** September 16, 2024 ** MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases MaxCyte and Kamau Therapeutics, a clinical-stage stem cell therapy gene correction company, announce they are entering into a strategic platform license (SPL) agreement. ](https://investors.maxcyte.com/news-releases/news-release-details/maxcyte-signs-strategic-platform-license-kamau-therapeutics)\n\n[ ![G-Rex logo](https://maxcyte.com/wp-content/uploads/2024/08/g-rex-logo-340.png) ** August 29, 2024 ** MaxCyte Announces Collaboration with ScaleReady to Participate in the G-Rex Grant Program MaxCyte’s electroporation expertise and equipment are available to all G-Rex grant recipients through an exclusive offer, including a discounted instrument, one pack of non-GMP processing assemblies and an ExPERT Platform Starter Pack. ](https://maxcyte.com/news/maxcyte-announces-collaboration-with-scaleready-to-participate-in-the-g-rex-grant-program/)\n\n[ ![](https://maxcyte.com/wp-content/uploads/2024/03/gen-news-1.png) ** June 27, 2024 ** GEN Article – Overcoming Viral Vector Risks James Brady, PhD, Senior Vice President at MaxCyte, highlights the risks of using viral vectors in cell and gene therapy (CGT) and provides electroporation as an alternative capable of reducing safety concerns, greater payload flexibility, and reduced production complexities. ](https://www.genengnews.com/topics/bioprocessing/overcoming-viral-vector-risks/)\n\n[ ![Icon stating \"in the news\"](https://maxcyte.com/wp-content/uploads/2024/03/inthenewsiconmm_1@2x-380x340.png) ** June 25, 2024 ** Porton Advanced introduces the MaxCyte ExPERT GTx Flow Electroporation platform Porton Advanced recently introduced the MaxCyte ExPERT GTx instrument to their cell therapy platform, marking the company as the first cell therapy CDMO in China to possess this clinical-grade Flow Electroporation system. ](https://portonadvanced.com/latest-news/porton-advanced-introduces-the-maxcyte-expert-gtx-flow-electroporation-instrument/)\n\n\n\n\nLoad More News\n\n[Electroporation Systems](/electroporation-systems/)\n\n[ ![ATx_03_shadow-132@2x](https://maxcyte.com/wp-content/uploads/2022/11/ATx_03_shadow-132@2x.jpg) ATx From small to medium static Electroporation. ](/electroporation-systems/atx/)\n\n[ ![STx_04_shadow@2x](https://maxcyte.com/wp-content/uploads/2022/11/STx_04_shadow@2x.jpg) STx Transfect up to 20 billion cells with scalable static or flow-through electroporation. ](/electroporation-systems/stx/)\n\n[ ![GTx_05_shadows@2x](https://maxcyte.com/wp-content/uploads/2022/11/GTx_05_shadows@2x.jpg) GTx Transfect up to 20 billion cells with our clinically validated and cGMP compliant flow-through electroporation. ](/electroporation-systems/gtx/)\n\n[ ![VLX-right-132@2x](https://maxcyte.com/wp-content/uploads/2022/11/VLX-right-132@2x.jpg) VLx For gram scale protein production. ](/electroporation-systems/vlx/)\n\n[Consumables](/consumables/)\n\n[ ![PA-Top-Image@2x](https://maxcyte.com/wp-content/uploads/2022/11/PA-Top-Image@2x.png) Processing Assemblies Achieve the desired scale and throughput with a range of consumable devices. ](/processing-assemblies/)\n\n[ ![Hyclone-cytiva-small@2x](https://maxcyte.com/wp-content/uploads/2022/11/Hyclone-cytiva-small@2x.png) Reagents & Supporting Products Complement your workflow with our flexible electroporation buffer formats and accessories. ](/consumables/pa-accessories/)\n\nNotifications\n"
        }
      ]
    },
    {
      "section_name": "Financial Reports",
      "links": [
        {
          "title": "Financial Reports",
          "url": "https://maxcyte.com/financial-information/financial-reports",
          "content": "[Skip to content](#fl-main-content)\n\n[ ![Group 167 \\(1\\)](https://maxcyte.com/wp-content/uploads/2022/11/Group-167-1.svg) ](/)\n\n[ Menu ](javascript:void\\(0\\) \"Click Here\")\n\n![Mobile logo](https://maxcyte.com/wp-content/uploads/2022/11/Mobile-logo.svg)\n\n  * Platforms\n    * [Back](#)\n    * [Electroporation Systems](/electroporation-systems/)\n  * Our Approach\n    * [Back](#)\n    * [Our Technology](/our-technology/)\n    * [Technical & Regulatory Support](/our-technology/technical-regulatory-support/)\n    * [Partnerships](/our-technology/partnerships)\n    * [Collaboration](/our-technology/collaboration)\n  * Who We Serve\n    * [Back](#)\n    * [Cell & Gene Therapy](/our-technology/cell-gene-therapy/)\n    * [Discovery](/our-technology/discovery-translational-research/)\n    * [Bioprocessing & Protein Production](/our-technology/bioprocessing-protein-production/)\n  * Learning Hub\n    * [Back](#)\n    * [Applications](/applications/)\n    * [Featured Science](/featured-science/)\n    * [Resource Library](/resource-library/)\n    * [Scientific Publications](/scientific-publications/)\n    * [Webinars & Presentations](/webinars-presentations/)\n    * [What cells can I use?](/what-cells-can-i-use/)\n  * [About Us](/about-us/)\n    * [Back](#)\n    * [Our History](/company-history/)\n    * [Our Team](/leadership/)\n    * [Board of Directors](/board-of-directors/)\n    * [Join our Team](/careers/)\n  * [Join Our Team](/careers/)\n  * News & Events\n    * [Back](#)\n    * [Press Releases](https://investors.maxcyte.com/news-events/news-releases/general)\n    * [Latest News](https://maxcyte.com/latest-news/)\n    * [Events](/events/)\n  * [Investors](https://investors.maxcyte.com/)\n  * [Contact Us](/contact/)\n    * [Back](#)\n    * [Ask the ExPERT](/contact/)\n    * [Request a Quote](/request-a-quote/)\n    * [Technical Support](/technical-support/)\n\n\n\n#  404 PAGE NOT FOUND\n\n##  Sorry! That page doesn't seem to exist.\n\n[Electroporation Systems](/electroporation-systems/)\n\n[ ![ATx_03_shadow-132@2x](https://maxcyte.com/wp-content/uploads/2022/11/ATx_03_shadow-132@2x.jpg) ATx From small to medium static Electroporation. ](/electroporation-systems/atx/)\n\n[ ![STx_04_shadow@2x](https://maxcyte.com/wp-content/uploads/2022/11/STx_04_shadow@2x.jpg) STx Transfect up to 20 billion cells with scalable static or flow-through electroporation. ](/electroporation-systems/stx/)\n\n[ ![GTx_05_shadows@2x](https://maxcyte.com/wp-content/uploads/2022/11/GTx_05_shadows@2x.jpg) GTx Transfect up to 20 billion cells with our clinically validated and cGMP compliant flow-through electroporation. ](/electroporation-systems/gtx/)\n\n[ ![VLX-right-132@2x](https://maxcyte.com/wp-content/uploads/2022/11/VLX-right-132@2x.jpg) VLx For gram scale protein production. ](/electroporation-systems/vlx/)\n\n[Consumables](/consumables/)\n\n[ ![PA-Top-Image@2x](https://maxcyte.com/wp-content/uploads/2022/11/PA-Top-Image@2x.png) Processing Assemblies Achieve the desired scale and throughput with a range of consumable devices. ](/processing-assemblies/)\n\n[ ![Hyclone-cytiva-small@2x](https://maxcyte.com/wp-content/uploads/2022/11/Hyclone-cytiva-small@2x.png) Reagents & Supporting Products Complement your workflow with our flexible electroporation buffer formats and accessories. ](/consumables/pa-accessories/)\n"
        }
      ]
    },
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Press Releases",
          "url": "https://investors.maxcyte.com/news-events/news-releases/all",
          "content": "[Skip to content](#lfg-main-content)\n\n[Skip to content](/#fl-main-content)\n\n[ ![Group 167 \\(1\\)](/sites/g/files/knoqqb82401/themes/site/client_site/dist/images/Group-167-1.svg) ](https://maxcyte.com/)\n\n[ Menu ](javascript:void\\(0\\))\n\n![Mobile logo](/sites/g/files/knoqqb82401/themes/site/client_site/dist/images/Mobile-logo.svg)\n\n  * [Platforms](/#)\n    * [Back](#)\n    * [Electroporation Systems](/#)\n  * [Our Approach](/#)\n    * [Back](#)\n    * [Our Technology](https://maxcyte.com/our-technology/)\n    * [Technical & Regulatory Support](https://maxcyte.com/our-technology/technical-regulatory-support/)\n    * [Partnerships](https://maxcyte.com/our-technology/partnerships)\n    * [Collaboration](https://maxcyte.com/our-technology/collaboration)\n  * [Who We Serve](/#)\n    * [Back](#)\n    * [Cell & Gene Therapy](https://maxcyte.com/our-technology/cell-gene-therapy/)\n    * [Discovery and Translational Research](https://maxcyte.com/our-technology/discovery-translational-research/)\n    * [Bioprocessing](https://maxcyte.com/our-technology/bioprocessing-protein-production/)\n  * [Learning Hub](/#)\n    * [Back](#)\n    * [Applications](https://maxcyte.com/applications/)\n    * [Featured Science](https://maxcyte.com/featured-science/)\n    * [Resource Library](https://maxcyte.com/resource-library/)\n    * [Scientific Publications](https://maxcyte.com/scientific-publications/)\n    * [Webinars & Presentations](https://maxcyte.com/webinars-presentations/)\n    * [What cells can I use?](https://maxcyte.com/what-cells-can-i-use/)\n  * [About Us](/#)\n    * [Back](#)\n    * [Our History](https://maxcyte.com/company-history/)\n    * [Our Team](https://maxcyte.com/leadership/)\n    * [Board of Directors](https://maxcyte.com/board-of-directors/)\n    * [Join our Team](https://maxcyte.com/careers/)\n  * [Join Our Team](https://maxcyte.com/careers/)\n  * [News & Events](/#)\n    * [Back](#)\n    * [Press Releases](/news-events/news-releases/all)\n    * [Latest News](https://maxcyte.com/latest-news/)\n    * [Events](/news-events/events)\n  * [Investors](/)\n  * [Contact Us](/#)\n    * [Back](#)\n    * [Ask the ExPERT](https://maxcyte.com/contact/)\n    * [Request a Quote](https://maxcyte.com/request-a-quote/)\n    * [Technical Support](https://maxcyte.com/technical-support/)\n\n\n\n#  News Releases\n\n  * [All Releases](/news-events/news-releases/all)\n  * [Financial](/news-events/news-releases/financial)\n  * [General](/news-events/news-releases/general)\n  * [RNS](/news-events/news-releases/rns)\n\n\n\nYear All202420232022202120202019201820172016\n\nAll\n\n[Holding(s) in Company](/news-releases/news-release-details/holdings-company-35)\n\nRNS Number : 0777O MaxCyte, Inc. 28 November 2024 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing \n\nNov 28, 2024 \n\n[Read More →](/news-releases/news-release-details/holdings-company-35)\n\n[Holding(s) in Company](/news-releases/news-release-details/holdings-company-36)\n\nRNS Number : 0780O MaxCyte, Inc. 28 November 2024 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing \n\nNov 28, 2024 \n\n[Read More →](/news-releases/news-release-details/holdings-company-36)\n\n[Holding(s) in Company](/news-releases/news-release-details/holdings-company-34)\n\nRNS Number : 7992M MaxCyte, Inc. 19 November 2024 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing \n\nNov 19, 2024 \n\n[Read More →](/news-releases/news-release-details/holdings-company-34)\n\n[MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics](/news-releases/news-release-details/maxcyte-celebrates-25-years-innovation-driving-cell-engineering)\n\nSince 1999, MaxCyte’s non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projects ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies \n\nNov 13, 2024 \n\n[Read More →](/news-releases/news-release-details/maxcyte-celebrates-25-years-innovation-driving-cell-engineering)\n\n[Filing of 10Q form](/news-releases/news-release-details/filing-10q-form)\n\nRNS Number : 2437L MaxCyte, Inc. 07 November 2024 MaxCyte announces filing of Form 10-Q for the quarterly period ended September 30, 2024 ROCKVILLE, MD , November 7, 2024 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform \n\nNov 07, 2024 \n\n[Read More →](/news-releases/news-release-details/filing-10q-form)\n\n[Third Quarter 2024 Financial Results](/news-releases/news-release-details/third-quarter-2024-financial-results)\n\nRNS Number : 2690L MaxCyte, Inc. 07 November 2024 MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance ROCKVILLE, MD , November 7, 2024 - MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform \n\nNov 07, 2024 \n\n[Read More →](/news-releases/news-release-details/third-quarter-2024-financial-results)\n\n[MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance](/news-releases/news-release-details/maxcyte-reports-third-quarter-2024-financial-results-and-updates)\n\nROCKVILLE, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics, today announced its \n\nNov 06, 2024 \n\n[Read More →](/news-releases/news-release-details/maxcyte-reports-third-quarter-2024-financial-results-and-updates)\n\n[Exercise of options and PDMR dealing](/news-releases/news-release-details/exercise-options-and-pdmr-dealing-20)\n\nRNS Number : 2188L MaxCyte, Inc. 06 November 2024 MaxCyte, Inc. (\" MaxCyte \" or the \"Company\") Exercise of options and PDMR dealing ROCKVILLE, MD , November 6, 2024 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies \n\nNov 06, 2024 \n\n[Read More →](/news-releases/news-release-details/exercise-options-and-pdmr-dealing-20)\n\n[Total Voting Rights](/news-releases/news-release-details/total-voting-rights-30)\n\nRNS Number : 8533K MaxCyte, Inc. 04 November 2024 MaxCyte, Inc. (\" MaxCyte \" or the \"Company\") Total Voting Rights ROCKVILLE, MD , November 4, 2024 : MaxCyte Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance \n\nNov 04, 2024 \n\n[Read More →](/news-releases/news-release-details/total-voting-rights-30)\n\n[MaxCyte to Participate in Two Upcoming Investor Conferences](/news-releases/news-release-details/maxcyte-participate-two-upcoming-investor-conferences-0)\n\nROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced \n\nOct 31, 2024 \n\n[Read More →](/news-releases/news-release-details/maxcyte-participate-two-upcoming-investor-conferences-0)\n\nDisplaying 1 - 10 of 488 \n\n  * [RSS Feeds](/rss-feeds)\n  * [Email Alerts](/ir-resources/email-alerts)\n  * [Contact IR](/ir-resources/contact-ir)\n  * [Search](/search)\n\n\n\n[Electroporation Systems](https://maxcyte.com/electroporation-systems/)\n\n[](https://maxcyte.com/electroporation-systems/atx/)\n\n![ATX_01](/sites/g/files/knoqqb82401/themes/site/client_site/dist/images/ATX_01.jpg)\n\nATx\n\nFrom small to medium static Electroporation.\n\n[](https://maxcyte.com/electroporation-systems/stx/)\n\n![STX_01](/sites/g/files/knoqqb82401/themes/site/client_site/dist/images/STX_01.jpg)\n\nSTx\n\nTransfect up to 20 billion cells with scalable static or flow-through electroporation.\n\n[](https://maxcyte.com/electroporation-systems/gtx/)\n\n![GTx](/sites/g/files/knoqqb82401/themes/site/client_site/dist/images/GTx.jpg)\n\nGTx\n\nTransfect up to 20 billion cells with our clinically validated and cGMP compliant flow-through electroporation.\n\n[](https://maxcyte.com/electroporation-systems/vlx/)\n\n![VLX](/sites/g/files/knoqqb82401/themes/site/client_site/dist/images/VLX.jpg)\n\nVLx\n\nFor gram scale protein production.\n\n[Consumables](https://maxcyte.com/consumables/)\n\n[](https://maxcyte.com/processing-assemblies/)\n\n![Processing Assemblies](/sites/g/files/knoqqb82401/themes/site/client_site/dist/images/Processing-Assemblies.png)\n\nProcessing Assemblies\n\nAchieve the desired scale and throughput with a range of consumable devices.\n\n[](https://maxcyte.com/consumables/reagents-supporting-materials/)\n\n![Accessories & Reagents](/sites/g/files/knoqqb82401/themes/site/client_site/dist/images/Accessories-Reagents.png)\n\nReagents & Supporting Products\n\nComplement your workflow with our flexible electroporation buffer formats and accessories.\n\nNotifications\n\n![Cookiebot session tracker icon loaded](https://imgsct.cookiebot.com/1.gif?dgi=00762995-4248-4b0d-bca9-ab54fabba0eb)\n"
        }
      ]
    },
    {
      "section_name": "Recent & Upcoming Events",
      "links": [
        {
          "title": "Stephens Annual Investment Conference",
          "url": "https://wsw.com/webcast/stph35/mxct/1850820",
          "content": "![Header Logo](images/logo.png)\n\n![](images/mobile-logo.png)\n\n# Register for the Stephens Annual Investment Conference | NASH2024\n\nMaxcyte, Inc. \n\nPresenting at: 11/19/2024 3:00 PM (CT)\n\nFirst Name First name required.\n\nLast Name Last name required.\n\nCompany Company name required.\n\nE-mail E-mail required. Email is not valid\n\nYou must have cookies enabled in order to register for this event.\n\n![Summitcast](/images/resources/images/summitcast_logo_sm_black.png)\n\n[![Summitcast](/images/resources/images/summitcast_logo_md_white.png)](https://twstevents.com/divisions/summitcast)© 2024 \n\ntwstevents.com - Unauthorized recording or downloading of this event is not permitted.\n\ntwstevents.com\n"
        },
        {
          "title": "Stifel 2024 Healthcare Conference",
          "url": "https://wsw.com/webcast/stifel96/mxct/2121576",
          "content": "![Header Logo](images/logo.png)\n\n![](images/mobile-logo.png)\n\n# Register for Stifel 2024 Healthcare Conference\n\nMaxcyte, Inc. \n\nPresenting at: 11/18/2024 10:55 AM (ET)\n\nFirst Name First name required.\n\nLast Name Last name required.\n\nCompany Company name required.\n\nE-mail E-mail required. Email is not valid\n\nYou must have cookies enabled in order to register for this event.\n\n![Summitcast](/images/summitcast_logo_sm_black.png)\n\n[![Summitcast](/images/resources/images/summitcast_logo_md_white.png)](https://twstevents.com/divisions/summitcast/)© 2024 \n\ntwstevents.com - Unauthorized recording or downloading of this event is not permitted.\n\ntwstevents.com\n"
        },
        {
          "title": "MaxCyte Third Quarter Earnings Conference Call",
          "url": "https://edge.media-server.com/mmc/p/4zsbqngi",
          "content": "Settings \n"
        }
      ]
    }
  ]
}